Bristol-Myers Squibb, Ventiv ink multi-year service deal

Share this article:
Bristol-Myers Squibb and Ventiv Pharma Services have signed a multi-year service agreement under which Ventiv will provide a sales force of more than 375 representatives focusing on Cefzil and Tequin.
Under the terms of the agreement, Ventiv Pharma also will provide BMS with the entire field and internal management staff, full operational support to include sales force automation, help desk support and analysis and reporting services, according to a Ventiv statement. Ventiv Pharma is a division of Ventiv Health Inc.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Channel

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...